A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative Colitis

• Status: Completed
• Trial end date: 2021-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Aims:Retrospectively observe the effects of Caltrate supplementation on the clinical effect of mesalazine in patients with ulcerative colitis.

Design: From January 2015 to December 2020, through retrieving the clinical database of the Second Affiliated Hospital of Wenzhou Medical University, patients with active UC who accepted mesalazine treatment were enrolled. According to whether Caltrate was supplemented at the same time, the patients were divided into supplementary group and non-supplementary group. The modified Mayo score and several laboratory indicators were compared between the two groups.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Wenzhou Medical University
• Treatments: Calcium Carbonate; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Clearly diagnosed patients with UC

• Took mesalazine for at least 12 months

Exclusion Criteria:

• had recent supplementation of vitD3

• had prior or concomitant use of other biologic agent, glucocorticoid and/or immunomodulators at the time of enrollment or follow up

• Co-morbid with other autoimmune diseases

• Severe liver and kidney dysfunction